Description

STORAGE
WYCHELM LABORATORIES LIMITED

Proven to minimise morbidity and mortality in Diabetic
CVD/CKD

• Controls towards normal HbA1C score consistently
• Shows betterment in CVD symptoms
• Significantly scores over Dapagliflozin in Type-2 Diabetes
• No major refractory CVD attack reported
• It treats type 2 diabetes
• It works in the kidneys to prevent absorption of glucose (blood sugar)
• It helps lower the blood sugar level